Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 13, 2004 - Issue 11
Submit an article Journal homepage
153
Views
76
CrossRef citations to date
0
Altmetric
Review

Recent developments in transient receptor potential vanilloid receptor 1 agonist-based therapies

Keith R Bley NeurogesX, Inc., 981F Industrial Road, San Carlos, CA 94070, USA. [email protected]
Pages 1445-1456 | Published online: 24 Feb 2005

Bibliography

  • CATERINA MJ, JULIUS D: The vanilloid receptor: a molecular gateway to the pain pathway. Ann. Rev Neuracci. (2001) 24:487–517.
  • •A comprehensive review of TRPV1 by those involved in its cloning and functional characterisation.
  • LOPEZ-RODRIGUEZ ML, VISO A, ORTEGA-GUTIERREZ S: VR1 receptor modulators as potential drugs for neuropathic pain. Mini Rev Med. Chem. (2003) 3:729–748.
  • •One of the few comprehensive reviews of all agonist and antagonist compounds.
  • PUNTAMBEKAR P, VAN BUREN J, RAISINGHANI M et al.: Direct interaction of adenosine with the TRPV1 channel protein. I Neurosci. (2004) 24:3663–3671.
  • CHEN SC, CHANG TJ, WU FS: Competitive inhibition of the capsaicin receptor-mediated current by dehydroepiandrosterone in rat dorsal root ganglion neurons. J. Pharmacol Exp. Ther. (2004) [Epub ahead of print].
  • CORTRIGHT DN, SZALLASI A: Biochemical pharmacology of the vanilloid receptor TRPV1. An update. Eur. Biochem. (2004) 271:1814–1819.
  • •An excellent review of the complex and numerous ways in which TRPV1 is regulated.
  • HOEGYES E: Beitrage zur physiologischen wirkung der bestandteile des capsicum annum. Arch. Exp. Patna Pharmacol (1878) 9:117–130.
  • JANCSO N: The role of sensory nerve endings in inflammatory reactions Bull. Millard Fillmore Hasp. (1960) 7:53-77. Expert Op/n. Investig. Drugs (2004) 13(11)1453
  • CATERINA MJ, SCHUMACHER MA, TOMINAGA M et al.: The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature (1997) 389:816–824.
  • STERNER 0, SZALLASI A: Novel natural vanilloid receptor agonists: new therapeutic targets for drug development. Trends Pharmacol Sci. (1999) 20:459–465.
  • CORDELL GA, ARAUJO OE: Capsaicin: identification, nomenclature, and pharmacotherapy. Ann. Pharmacother. (1993) 27:330–336.
  • TEWKSBURY JJ, NABHAN GP: Seed dispersal. Directed deterrence by capsaicin in chilies. Nature (2001) 412:403–404.
  • JORDT SE, JULIUS D: Molecular basis for species-specific sensitivity to 'hot' chili peppers. Cell (2002) 108:421–430.
  • KENNEDY WR: Opportunities afforded by the study of unmyelinated nerves in skin and other organs. Muscle Nerve (2004) 29:756–767.
  • •A comprehensive discussion of techniques for quantification of nociceptors in skin and other organs.
  • SIMONE DA, NOLANO M, JOHNSON T et al.: Intradermal injection of capsaicin in humans produces degeneration and subsequent reinnervation of epidermal nerve fibers: correlation with sensory function. J. Neurosci. (1998) 18:8947–8959.
  • DUX M, SANN H, SCHEMANN M et al.: Changes in fibre populations of the rat hairy skin following selective chemodenervation by capsaicin. Cell Tissue Res. (1999) 296:471–477.
  • STANDER S, MOORMANN C, SCHUMACHER M et al.: Expression of vanilloid receptor subtype 1 in cutaneous sensory nerve fibers, mast cells, and epithelial cells of appendage structures. Exp. Dermatol. (2004) 13:129–139.
  • MORBIN M, CAPOBIANCO R, BORGNA M et al.: Painful diabetic neuropathy (PDNI): a morphological study of capsaicin receptor distribution. J. Peripheral Nervous System. (2004) 9:119–120.
  • PETERSEN KL, RICE FL, SUESS F et al.:Relief of postherpetic neuralgia by surgical removal of painful skin. Pain (2002) 98:119–126.
  • SOUTHALL MD, LIT, GHARIBOVA LS et al.: Activation of epidermal vanilloid receptor-1 induces release of proinflammatory mediators in human keratinocytes. Pharmacol. Exp. Ther (2003) 304:217–222.
  • KO F, DIAZ M, SMITH P et al.: Toxic effects of capsaicin on keratinocytes and fibroblasts. J. Burn Care Rehabil. (1998) 19:409–413.
  • AVELINO A, CRUZ C, NAGY I et al.: Vanilloid receptor 1 expression in the rat urinary tract. Neuroscience (2002) 109(4):787–98.
  • DE GROAT WC: A neurologic basis for the overactive bladder. Urology (1997) 50(6A Suppl.):36–52.
  • •Provides one of the best overviews of the neural pathways involved in bladder regulation.
  • BIRDER LA, NAKAMURA Y, KISS S et al.: Altered urinary bladder function in mice lacking the vanilloid receptor TRPV1. Nat. Neurosci. (2002) 5:856–860.
  • BIRDER LA, KANAI AJ, DE GROAT WC et al.: Vanilloid receptor expression suggests a sensory role for urinary bladder epithelial cells. Proc. Nati Acad. Sci. USA (2001) 98:13396–13401.
  • CRUZ F: Mechanisms involved in new therapies for overactive bladder. Urology (2004) 63(3 Suppl. 1):65–73.
  • •A very up-to-date and comprehensive review of TRPV1 agonist-based therapies and the pathophysiology of neurogenic bladder disorders.
  • TYMPANIDIS P, TERENGHI G, DOWD P: Increased innervation of the vulval vestibule in patients with vulvodynia. Br. J. Dermatol. (2003) 148:1021–1027.
  • TYMPANIDIS P, CASULA MA, YIANGOU Y et al.: Increased vanilloid receptor VR1 innervation in vulvodynia. Eur. J. Path (2004) 8:129–133.
  • SCHMIDT RF: The articular polymodal nociceptor in health and disease. Prog. Brain Res. (1996) 113:53–81.
  • MACH DB, ROGERS SD, SABIN° MC et al.: Origins of skeletal pain: sensory and sympathetic innervation of the mouse femur. Neuroscience (2002) 113:155–166.
  • NIV D, GOFELD M, DEVOR M: Causes of pain in degenerative bone and joint disease: a lesson from vertebroplasty. Path (2003) 105:387–392.
  • •Brings together new insights into the mechanisms of bone pain.
  • LIU M, LIU MC, MAGOULAS C et al.: Versatile regulation of cytosolic Ca2' by vanilloid receptor 1 in rat dorsal root ganglion neurons. J. Biol. Chem. (2003) 278:5462–5472.
  • SZALLASI A, BLUMBERG PM: Vanilloid (capsaicin) receptors and mechanisms. Pharmacol. Rev (1999) 51:159–212.
  • •Although somewhat out of date, this remains the most comprehensive review of the vanilloid field. It is available free online (http://pharmrev.aspetjournals.org/cgi/ content/full/51/2/159).
  • MICHAELIS M: Electrophysiological characteristics of injured peripheral nerves. In: Mechanisms and Mediators of Neuropathic Pain. AB Malmberg, SR Chaplan (Eds), Birkhaeuser Verlag, Basel, Switzerland (2002).
  • ROWBOTHAM MC, YOSIPOVITCH G, CONNOLLY MK et al.: Cutaneous innervation density in the allodynic form of postherpetic neuralgia. Neurobiol. Dis. (1996) 3:205–214.
  • OAKLANDER AL: The density of remaining nerve endings in human skin with and without postherpetic neuralgia after shingles. Path (2001) 92:139–145.
  • KENNEDY WR, WENDELSCHAFER-CRABB G, JOHNSON T: Quantitation of epidermal nerves in diabetic neuropathy. Neurology (1996) 47:1042–1048.
  • POLYDEFKIS M, YIANNOUTSOS CT, COHEN BA et al.: Reduced intraepidermal nerve fiber density in HIV-associated sensory neuropathy. Neurology (2002) 58:115–119.
  • LINDENLAUB T, SOMMER C: Epidermal innervation density after partial sciatic nerve lesion and pain-related behavior in the rat. Acta. Neuropathol. (2002) 104:137–143.
  • CAMPBELL JN: Nerve lesions and the generation of pain. Muscle Nerve (2001) 24:1261–1273.
  • •Summarises the data suggesting that hyperactivity of residual intact nociceptors is the primary driver of peripheral neuropathic pain syndromes.
  • MILLER MS, BUCK SH, SIPES IG et al.: Regulation of substance P by nerve growth factor: disruption by capsaicin. Brain Res. (1982) 250:193–196.
  • PETRUSKA JC, MENDELL LM: The many functions of nerve growth factor: multiple actions on nociceptors. Neurasci Lett. (2004) 361:168–171.
  • BJERRING P, ARENDT-NIELSEN L, SODERBERG U: Argon laser induced cutaneous sensory and pain thresholds in post-herpetic neuralgia. Quantitative modulation by topical capsaicin. Acta. Derm. Venereol (1990) 70:121–125.
  • NOLANO M, SIMONE DA, WENDELSCHAFER-CRABB G et al: Topical capsaicin in humans: parallel loss of epidermal nerve fibers and pain sensation. Path (1999) 81:135–145.
  • TURNBULL A: Tincture of capsaicin as a remedy for chilblains and toothache. Dublin Free Press (1850) 1:95–96.
  • MASON L, MOORE RA, DERRY S et al.: Systematic review of topical capsaicin for the treatment of chronic pain. Br. Med. (2004) 328:991–994.
  • McMAHON SB, LEWIN G, BLOOM SR: The consequences of long-term topical capsaicin application in the rat. Path (1991) 44:301–310.
  • BJERRING P, ARENDT-NIELSEN L: Useof a new argon laser technique to evaluate changes in sensory and pain thresholds in human skin following topical capsaicin treatment. Skin Pharmacol (1989) 2:162–167.
  • WALKER FO, LEWIS SF: Somesthetic andelectrophysiologic effects of topical 0.025% capsaicin in man. Reg. Ariesth. (1990) 15:61–66.
  • SIMONE DA, OCHOA J: Early and lateeffects of prolonged topical capsaicin on cutaneous sensibility and neurogenic vasodilatation in humans. Pain (1991) 47:285–294.
  • CATERINA MJ, ROSEN TA, TOMINAGA M et al.: A capsaicin-receptor homologue with a high threshold for noxious heat. Nature (1999) 398:436–441.
  • SERRA J, CAMPERO M, OCHOA J: Flare and hyperalgesia after intradermal capsaicin injection in human skin. Neurophysiol (1998) 80:2801–2810.
  • PAICE JA, FERRANS CE, LASHLEY FR et al.: Topical capsaicin in the management of HIV-associated peripheral neuropathy. J. Path Symptom Manage. (2000) 19:45–52.
  • MAGGI CA, BARBANTI G, SANTICIOLI P et al: Cystometric evidence that capsaicin-sensitive nerves modulate the afferent branch of micturition reflex in humans. I Urol. (1989) 142:150–154.
  • CHANCELLOR MB, DE GROAT WC: Intravesical capsaicin and resiniferatoxin therapy: spicing up the ways to treat the overactive bladder. J. Urol. (1999) 162:3–11.
  • •A seminal review of the urological applications of TRPV1 agonists.
  • DASGUPTA P, CHANDIRAMANI VA, BECKETT A et al: The effect of intravesical capsaicin on the suburothelial innervation in patients with detrusor hyper-reflexia. BJUInt. (2000) 85:238–245.
  • JANUSZ JM, BUCKWALTER BL, YOUNG PA et al: Vanilloids. 1. Analogs of capsaicin with antinociceptive and antiinflammatory activity. I Med. Chem. (1993) 36:2595–2604.
  • LIU L, LO Y, CHEN I, SIMON SA: The responses of rat trigeminal ganglion neurons to capsaicin and two nonpungent vanilloid receptor agonists, olvanil and glyceryl nonamide. Neurosci. (1997) 17:4101–4111.
  • URBAN L, DRAY A: Capsazepine, a novelcapsaicin antagonist, selectively antagonises the effects of capsaicin in the mouse spinal cord in vitro. Neurosci. Lett. (1991) 134:9–11.
  • URBAN L, CAMPBELL EA, PANESARM et al: hi vivo pharmacology of SDZ 249-665, a novel, non-pungent capsaicin analogue. Pain (2000) 89:65–74.
  • SZALLASI A, BLUMBERG PM: Resiniferatoxin, a phorbol-related diterpene, acts as an ultrapotent analog of capsaicin, the irritant constituent in red pepper. Neuroscience (1989) 30:515–520.
  • WENDER PA, JESUDASON CD, NAKAHIRA H et al.: The first synthesis of a daphnane diterpene: the enantiocontrolled total synthesis of (1-resiniferatoxin. J. Amer. Chem. Soc. (1997) 119:12976–12977.
  • LAZZERI M, BENEFORTI P, TURINI D: Urodynamic effects of intravesical resiniferatoxin in humans: preliminary results in stable and unstable detrusor. Urol. (1997) 158:2093–2096.
  • CHANCELLOR MB: Discussion: resiniferatoxin-preliminary data. Urology (2000) 55(5A Suppl.):65.
  • GIANNANTONI A, DI STASI SM, STEPHEN RL et al: Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study. J. Urol. (2004) 172:240–243.
  • KIM JH, RIVAS DA, SHENOT PJ et al: Intravesical resiniferatoxin for refractory detrusor hyperreflexia: a multicenter, blinded, randomized, placebo-controlled trial. J. Spinal Cord Med. (2003) 26:358–363.
  • HUA XY, CHEN P, HWANG J et al: Antinociception induced by civamide, an orally active capsaicin analogue. Pain (1997) 71:313–322.
  • DIAMOND S, FREITAG F, PHILLIPS SB et al: Intranasal civamide for the acute treatment of migraine headache. Cephalalgia (2000) 20:597–602.
  • SAPER JR, KLAPPER J, MATHEW NT et al: Intranasal civamide for the treatment of episodic cluster headaches. Arch. Neurol (2002) 59:990–994.
  • BOURNE N, BERNSTEIN DI, STANBERRY LR: Civamide (cis-capsaicin) for treatment of primary or recurrent experimental genital herpes. Antimicrob. Agents Chemother. (1999) 43:2685–2688.
  • ARNAR DO, CAI JJ, LEE HC et al: Electrophysiologic effects of civamide (zucapsaicin) on canine cardiac tissue in vivo and in vitro. I Cardiovasc. Pharmacol (1998) 32:875–883.
  • CHENG YP, WANG YH, CHENG LP et al: Electrophysiologic effects of capsaicin on pacemaker cells in sinoatrial nodes of rabbits. Acta Pharmacol Sin. (2003) 24:826–830.
  • ROBBINS WR, STAATS PS, LEVINE J et al: Treatment of intractable pain with topical large-dose capsaicin: preliminary report. Anesth. Analg. (1998) 86:579–583.
  • MALMBERG AB, MIZISIN AP, CALCUTT NA et al: Reduced heat sensitivity and epidermal nerve fiber immunostaining following single applications of a high-concentration capsaicin patch. Pain (2004) 111:360–367.
  • MALAN TP, TUCHMAN M, MOLLEN M et al: A single one-hour application of high-concentration trans-capsaicin patches leads to four weeks of pain relief in postherpetic neuralgia (PHN) patients. World Congress of Anesthesiology Paris, France (2004).
  • LEE JJ, SHIM HJ, KIM SH et al: Pharmacokinetics of a non-narcotic analgesic, DA-5018, in rats. Biopharm. Drug Dispos. (1998) 19:101–108.
  • KIM DH, AHN BO, KIM SH et al: Antipruritic effect of DA-5018, a capsaicin derivative, in mice. Arch Pharm Res. (1999) 22:549–653.
  • CHA BJ, LEE ED, KIM WB et al: Enhanced skin permeation of a new capsaicin derivative (DA-5018) from a 1455 binary vehicle system composed of isopropyl myristate and ethoxydiglycol. Arch. Pharm. Res. (2001) 24:224–228.
  • KARAT L, BROWN DC, MANNES AJ et al: Deletion of vanilloid receptor 1-expressing primary afferent neurons for pain control. J. Clin. Invest. (2004) 113:1344–1352.
  • VESALUOMA M, MULLER L, GALLAR J et al.: Effects of oleoresin capsicum pepper spray on human corneal morphology and sensitivity. Invest Ophthalmol. Vis. Sci. (2000) 41:2138-2147. Websites

Websites

  • http://europa.eu.int/comm/food/fs/sc/scf/ out120_en.pdf European Commission Scientific Committee on Food. Opinion of the Scientific Committee on Food on capsaicin.
  • http://www.algorx.com/ AlgorRx Pharmaceuticals website.
  • http://www.winstonlaboratories.com/ Winston Laboratories website.
  • http://www.pslgroup.com/dg/13DF62.htm Doctor's Guide.
  • http://www.clinicaltrials.gov/ct/show/ NCT00077935?order=4 Clinical trials website.
  • http://www.retroconference.org/ 192004/cd/ PDFs/490.pdf Novel high-concentration capsaicin patch for the treatment of painful HIV-assiciated distal symmetrical polyneuropathy: results of an open label trial. SIMPSON D, BROWN S, SAMPSON J et al. (2004). Online version.
  • http://www.neurogesx.com Neurogesx website.
  • http://www.donga.co.kr/ Dong-A Pharmaceuticals website. Affiliation

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.